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ABSTRACT
The aims of the present study were to evaluate the performance of the main methods proposed for the comparison of 
percentage dissolved versus time curves and to recommend a more biorelevant combined approach for the comparison of 
dissolution profiles of multisource drug products. In vitro dissolution tests of four brands of oxcarbazepine (OxCBZ) tablets 
were performed, and the resulting profiles were compared by model-independent, model-dependent, and ANOVA-based 
statistical methods. After a careful analysis of the results, some methods were chosen and applied to the comparison of dis-
solution profiles of four brands of carbamazepine (CBZ) tablets and two brands of phenytoin (PHT) capsules. Finally, these 
in vitro results were qualitatively correlated with the corresponding in vivo results previously obtained with the same CBZ 
and PHT products assayed in healthy volunteers. The analysis of the dissolution data obtained with OxCBZ tablets allowed 
discarding the ANOVA-based statistical methods since in all cases they were over-discriminating from a biopharmaceutical 
point of view. The remaining comparison methods were applied to in vitro profiles of CBZ and PHT products and the results 
correlated with in vivo data. The most suitable methods for the biopharmaceutical comparison of in vitro dissolution profiles 
were the model-independent ones, and among them, the best correlations were the f2 similarity factor along with a measure 
of the dissolution extent (e.g., area under the curve). This combined approach gives a robust and informative result with the 
most biopharmaceutical relevance.
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INTRODUCTION
Evaluation of dissolution has approximately a century of development. However, in recent decades it has attracted more interest for its application to the 
study of solid drug products. Active ingredients included 
in a pharmaceutical form must be released and dissolved 
prior to absorption. Thus, dissolution studies may be 
related to the bioavailability of the drugs in the body. The 
rate at which poorly water-soluble drugs are dissolved in 
the gastrointestinal tract from the dosage form is corre-
lated with the rate of systemic absorption (1). Therefore, 
the in vitro dissolution test has become the most suitable 
tool to predict the way that a drug product will behave in 
vivo (at least for highly permeable drugs). 
Over time, dissolution studies have expanded beyond 
tablets and capsules to encompass modified-release 
products, transdermal products, and oral suspensions, 
among others. The relevance of in vitro dissolution stud-
ies of pharmaceuticals has been increasing over time, 
and these studies even replace in vivo studies in certain 
circumstances (2). On the other hand, the discussion 
about what methods should be used to compare dissolu-
tion data and what similarity criteria should be applied 
has also grown.
Since the 1990s, many proposals of methods useful for 
the comparison of dissolution profiles began to appear 
in the scientific literature (3–10). New methods (11–15) 
continued to emerge even after drug regulatory agen-
cies recommended the similarity factor (f2) developed by 
Moore and Flanner (4) as the preferred method for dis-
solution profile comparison (16–18). Most of the proposed 
methods fall into one of three categories:
Model-independent methods: These methods com-
pare dissolution profiles without fitting the data to an 
equation that represents them. This category includes 
mathematical methods like the difference/similarity fac-
tors f1 and f2 (4) or the Rescigno indexes ξi (19), along with 
the statistical comparisons of parameters obtained from 
the profiles, such as the area under the curve (AUC) and 
dissolution efficiency (DE). 
ANOVA-based statistical methods: These methods 
treat the percentage dissolved as a random variable to 
perform the analysis of variance, consider the formula-
tion as a single class variable (one-way ANOVA) and thus 
perform time-to-time comparisons, or consider both the 
formulation and the time as class variables (two-way 
ANOVA) under the null hypothesis of similarity. However, 
its application is not strictly correct because it does not 
fulfill the assumption of independent variables due to 
the correlation between the percentage dissolved and 
time (20).
Model-dependent methods: These methods include 
different forms for profile comparison that rely on a previ-
ous stage of fitting dissolution data to an equation that *Corresponding author.
e-mail: eruiz@biol.unlp.edu.ar
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describe its temporal evolution. After the data have been 
fit, they can be compared with several statistical methods, 
such as Hotelling’s T2 test (21) and the “Regions of Similar-
ity” method (5).
In the present work, the suitability of several methods 
proposed for the comparison of dissolution profiles 
from a biopharmaceutical approach was assessed. The 
results obtained were compared to evaluate their cor-
respondence, applications, advantages, and limitations. 
Moreover, the biopharmaceutical relevance of the results 
was addressed by means of their correlation with in vivo 
results previously obtained, with the aim of proposing a 
more biorelevant combined approach for the compari-
son of in vitro dissolution profiles of multisource drug 
products.
MATERIALS AND METHODS
Equipment and Materials
Dissolution tests were conducted in a Sotax AT 7 appa-
ratus (Sotax AG, Basel, Switzerland). The amount dissolved 
was determined spectrophotometrically in a Thermo 
spectrophotometer, Helios-Beta model (Thermo Fisher 
Scientific, Waltham, MA, USA). Drugs and reagents were 
weighed on a Mettler Toledo AG 204 balance (Mettler, 
Greinfensee, Switzerland).
All medications (oxcarbazepine and carbamazepine 
tablets, and phenytoin capsules) were purchased at a local 
drugstore. Reference standards of all four drugs were pur-
chased from the Argentinean National Institute of Medica-
tions (Buenos Aires, Argentina). All other chemicals used 
were of analytical grade.
Dissolution Studies
Dissolution profiles were obtained for the following 
medications: oxcarbazepine 600- and 300-mg tablets (3 
brands and 1 brand, respectively), carbamazepine 200-mg 
tablets (4 brands), and sodium phenytoin 100-mg cap-
sules (2 brands). 
All dissolution tests were conducted according to USP 
34 (22). In the case of oxcarbazepine products, which are 
not included in any pharmacopeia, the conditions speci-
fied for CBZ were applied: USP Apparatus 2 (paddle) at 
75 rpm with 900 mL of 1% sodium lauryl sulfate (LSNa) 
as dissolution medium. The dissolution test conditions of 
sodium phenytoin capsules were USP Apparatus 1 (bas-
ket) at 50 rpm with 900 mL of distilled water as dissolution 
medium.  
In all cases, media were deaerated and filtered with a 
0.45-µm nylon filter prior to use. Bath temperature was 
set at 37 ± 0.5 °C. Samples (5-mL) were drawn at each 
sampling time and immediately centrifuged at 3500 rpm. 
Trials were performed with twelve tablets or capsules, and 
the mean values were used for data analysis. 
A short validation program was performed for the three 
different spectrophotometric methods employed for the 
determination of the percentage dissolved. Linearity, 
precision, and specificity were assessed for each medium–
wavelength combination: 1% LSNa at 285 and 256 nm for 
CBZ and OxCBZ, respectively, and distilled water at 258 
nm for PHT.
Data Analysis
The dissolution profiles of OxCBZ products were ana-
lyzed by the following methods.
Model-Independent Methods
The similarity (f2) and difference (f1) factors (4) were 
calculated for all possible pairs of products considered. 
The f2 value was computed with the points of the dis-
solution profile up to the moment in which the product 
acting as reference in such comparison dissolved 85% or 
more. Both products in each pair were taken as reference 
in a comparison; therefore, two f2 values were computed 
for each pair. Rescigno indexes (ξi) were not applied 
since there is no decision criterion about the cutoff value 
to establish similarity between the profiles being com-
pared. Equation 1 describes how to calculate f2, while f1 
is shown in eq 2 (Rt and Tt are the average percentages 
dissolved at time t of the reference and test products, 
respectively).
 (1)
  (2)
The profiles were considered similar if f2 was greater than 
or equal to 50 and f1 less than 15 (16).
In another model-independent method, the values of 
area under the curve (AUC) were obtained, calculated by 
the method of trapezoids, and the dissolution efficiency 
(DE) calculated according to eq 3:
  
(3)
where %Dt is the percentage dissolved at time t, %Dmax 
is the maximum dissolved at the final time T, and AUC0-T 
is the area under the curve from zero to T. After AUC and 
DE for each individual tablet of each formulation were 
obtained, they were statistically compared by calculating 
the ANOVA and the 90% confidence interval (90% CI) for 
the ratio of the means.
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ANOVA-Based Methods
For all possible pairs of products, two-way ANOVA 
was performed considering the percentage dissolved as 
the random variable, and Formulation and Time as class 
variables (factors). Due to the existence of replicates 
(individual tablets), the effect of the Formulation*Time 
interaction was evaluated. A one-way ANOVA (single 
factor: Formulation) was also performed by comparing 
the percentage dissolved between formulations at each 
time point. 
Model-Dependent Methods
As mentioned in the introduction, this classification in-
cludes different methods of statistical comparisons (mul-
tivariate in most cases) that require fitting the dissolution 
curves to equations or models that represent them. Table 
1 presents the nonlinear mathematical models tested for 
fitting the experimental data. 
Although other mathematical models have been postu-
lated for fitting the percent dissolved versus time data 
(13, 23), the four equations presented in Table 1 are the 
most frequently used due to their good fit to immediate-
release solid form dissolution data. In general, there is no 
universal model to fit all dissolution profiles, and there 
are no established criteria to select the proper mathemat-
ical model.
To choose the best-fitting equation, average data 
(n = 12) obtained for each product were fit with two statis-
tical software packages, Systat v.12 and Infostat v.2011e. 
In all cases, the %Dmax parameter was fixed at 100 since 
the equations had to be biparametric for the subsequent 
statistical comparison, and the same weight was assigned 
to all points. After each fitting was performed, it was veri-
fied that both programs yielded matching results, which 
was true in all cases.
The parameter values obtained for each product with 
each equation were recorded as well as the coefficient 
of determination (R2) and the AIC (Akaike’s Information 
Criterion). The AIC is widely used as a criterion for select-
ing the model that better fits a particular set of data, 
especially when the models considered do not contain 
the same number of parameters, as in this case. Given a 
set of models, the best fit is the one with the lowest AIC 
value (24).
The R2 and AIC obtained as described above allowed a 
first discard of some of the assayed equations. To decide 
among the remaining ones, the statistical test of “lack of 
fit” (25) was performed on the dissolution data fit to the 
equations to statistically assess whether the adjustment 
was acceptable in all cases (i.e., if the model was ap-
plicable to the dissolution data of all the assayed prod-
ucts). Once the mathematical method was selected, the 
equation parameters of each tablet were recorded and 
statistically compared between products by means of the 
following tests:
Hotelling T2 statistic: This distribution was developed 
by Harold Hotelling as a generalization of the t-distribu-
tion, to be applied to multivariate analysis (26). The T2 sta-
tistic can be calculated by the following expression (eq 4):
 (4)
Differences between the mean sample vectors are first 
recorded, and then the variance–covariance matrix (Sp) 
is calculated and multiplied by the sum of the inverses 
of the sample sizes (1/n1 + 1/n2). The resulting matrix is 
inverted and multiplied by the calculated average differ-
ence. For large samples, the statistic will follow a chi-
square distribution with p degrees of freedom (where p 
is the number of variables). However, this approach does 
not take into account the variation due to the estimation 
of the variance–covariance matrix. Therefore, it transforms 
into an F-statistic according to eq 5:
 
  
(5)
Comparison by similarity regions: This method, 
proposed by Sathe et al. (5), involves defining similarity 
regions for the model parameters based on the results 
obtained for the reference. As in this work, three regions 
were considered: ±σ, ±2σ, and ±3σ, with σ being the 
standard deviation obtained for the reference product for 
a given parameter. These regions are rectangles; in one 
direction are plotted the deviations of the one parameter 
and in the other, those of the other parameter (of the 
reference product). Then, to compare each pair, the differ-
ences of parameters a and b (ln-transformed) and the 90% 
confidence intervals of these differences are calculated 
and then verified whether they were inside or outside the 
previously defined regions. A schematic example of this 
method is presented in Figure 1.
Table 1. Mathematical Models and Respective Equations Used 
for Fitting the Dissolution Data
Model Equation
First Order
Gompertz
Logistic
Weibull
%Dt: percentage dissolved at time t; %Dmax: maximum dissolved at the final 
time; K, a, and b: parameters of the equations.
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RESULTS
OxCBZ Tablets
Figure 2 presents the dissolution profiles in 1% LSNa 
of OxCBZ products: 600-mg tablets (products J*, K, and L; 
the asterisk indicates the reference) and 300-mg tablets 
(product M). The results of fitting the four proposed equa-
tions (first-order, Gompertz, Weibull, and Logistic) to those 
profiles are summarized in Table 2.
As shown in Table 2, the R2 coefficient is higher than 
0.995 and the AIC values are comparable in all cases. 
Moreover, there are no systematic trends in the residual 
plots (not shown).
The first-order equation was discarded because it 
yielded the lowest R2 values, and in most cases, the result-
ing AIC values were higher than those of other methods 
(lower AIC values are expected for a first-order equation 
Figure 1. Regions of similarity defined according to the variability in the 
equation parameters for the reference product (white rectangles). The 
gray rectangles represent the regions of 90% confidence interval for the 
difference in the parameters between two given products, not similar (light 
gray) or similar (dark gray).
Figure 2. Dissolution profiles in 1% LSNa of OxCBZ tablets: J *, K and L of 
600 mg, product M of 300 mg. The asterisk denotes the reference product.
Table 2. Results of Fitting the Four Mathematical Models to the OxCBZ Dissolution Profiles
Product First Order Gompertz Logistic Weibull
OxCBZ-J*
k = 0.1223 a = 31.88 a = -4.616 a = 0.0382
b = 5.030 b = 5.952 b = 1.556
R2 = 0.9985 R2 = 0.99997 R2 = 0.99996 R2 = 0.99992
AIC = 30.10 AIC = 5.25 AIC = 4.82 AIC = 13.10
OxCBZ-K
k = 0.0875 a = 11.19 a = -3.580 a = 0.0775
b = 3.271 b = 4.041 b = 1.051
R2 = 0.9994 R2 = 0.99997 R2 = 0.99993 R2 = 0.9994
AIC = 21.87 AIC = 23.44 AIC = 19.03 AIC = 24.66
OxCBZ-L
k = 0.0440 a = 22.98 a = -6.208 a = 0.0132
b = 4.656 b = 5.042 b = 1.371
R2 = 0.9971 R2 = 0.9955 R2 = 0.9980 R2 = 0.9995
AIC = 34.93 AIC = 41.67 AIC = 36.41 AIC = 24.00
OxCBZ-M
k = 0.0551 a = 39.78 a = -6.276 a = 0.0127
b = 3.699 b = 5.492 b = 1.498
R2 = 0.9968 R2 = 0.9971 R2 = 0.9990 R2 = 0.9998
AIC = 36.14 AIC = 40.98 AIC = 32.03 AIC = 17.51
* reference product
R2: coefficient of determination; AIC: Akaike’s Information Criterion; k, a, b: parameters of the equations.
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since it has only one parameter, k). The Gompertz equa-
tion fit well to the first two products data (J* and K) but 
not to OxCBZ-L and M, for which the AIC values were too 
high. Further analysis showed that this lack of fit was due 
to fixing the %Dmax value to 100, since when making the 
adjustment with the triparametric equation, both pro-
grams estimated a %Dmax value close to 110 to achieve 
convergence (for products L and M).
Elements to decide between the Logistic and Weibull 
equations do not arise from the data presented in Table 2. 
While the first seems to fit best to the J* and K products, 
the second corresponds to L and M products. A lack-of-fit 
statistical analysis (25) was performed to decide between 
both equations, and the results are shown in Table 3.
By this assay, two null hypotheses were simultaneously 
tested: the non-correlation, which should be rejected in 
favor of the correlation between the time and percentage 
dissolved, and the fitting to the selected equation, which 
must be accepted to assert that the model chosen is cor-
rect. While the non-correlation was rejected in all cases, 
the fit hypothesis could not be accepted in two cases: the 
Logistic equation assayed in products L and M (p < 0.001). 
Therefore, dissolution profiles of each individual tablet 
of the four OxCBZ products were then fitted to the Weibull 
equation to obtain a mean value (n = 12) of the param-
eters a and b for each product. With these values (ln-trans-
formed), the Hotelling’s T2 test and the comparison by 
similarity regions methods were performed as described 
in Materials and Methods—Data Analysis section.
Tables 3–6 present the results and conclusions of all the 
applied methods, grouped by pairs of product compared. 
Although there are six different possible pairs for four 
products (J *, K, L, and M), only four tables are presented. 
The two remaining ones (corresponding to J*-L and K-L 
pairs) are omitted since consistent results (not similarity) 
were obtained among all the applied methods.
In first place, each table presents the values obtained 
for the calculated mathematical indexes and the conclu-
sion of similarity or not according to the correspondent 
specifications. When the similar/not similar conclusion 
depended on what product was considered as reference, 
“not determined” (ND) was placed. In the case of DE and 
AUC comparisons, the value of the ratio between the two 
considered products for each of these parameters, the 
90% confidence interval for this ratio (90% CI), and the p 
value are shown. Since the null hypothesis established 
that there were no significant differences between two 
given parameters, the profiles were considered similar if 
p > 0.05.
In the second place, the results of the ANOVA-based 
statistical methods are presented, and in the third place 
are the results of the model-dependent comparisons. The 
difference in ln-transformed parameters of the Weibull 
equation (a and b) between products with its correspond-
ing 90% CI are presented. According to the region-of-
similarity method (5), profiles were considered similar 
if the 90% CI of a and b were simultaneously included 
within a given region previously defined as a function of 
the standard deviation of the reference product (σ). In this 
case, these regions were:
Considering ±1σ: [-0.520, +0.520] for a and [-0.107, 
+0.107] for b
Considering ±2σ: [-1.040, +1.040] for a and [-0.214, 
+0.214] for b
Considering ±3σ: [-1.560, +1.560] for a and [-0.321, 
+0.321] for b
The results of the Hotelling’s statistical test are also 
presented (the F value, calculated according to eq 5), fol-
lowed by the corresponding critical F. The null hypothesis 
of similarity (H0: µ1 = µ2) is rejected if the calculated F is 
greater than the critical one (i.e., p < 0.001).
CBZ Tablets
Figure 3 shows the dissolution profiles of the four 200-
mg CBZ products in 1% LSNa. These products were the 
same assayed in vivo in a relative bioavailability study 
performed in healthy volunteers (27).
When the mathematical models already described for 
OxCBZ were fitted to the CBZ dissolution profiles, none 
of the four equations had clear advantages over others 
according to the R2 and AIC criteria, so that the four were 
subjected to the lack-of-fit test (25) to decide between 
them.
As shown in Table 7, it was not possible to fit a single 
model to the data of all four products (CBZ-B dissolution 
profile does not fit any equation). Furthermore, results 
obtained for OxCBZ suggest that both model-dependent 
and ANOVA-based statistical methods are so discriminat-
ing that the differences usually found in products from 
different origins, although biopharmaceutically irrelevant, 
do not confirm similarity.
Hence, the comparisons of CBZ product dissolution pro-
files were performed only by model-independent meth-
ods, and the same similarity criteria described earlier for 
OxCBZ were applied. The results are presented in Table 8.
PHT Capsules
The dissolution profiles in water of the two PHT 100-mg 
capsules assayed are shown in Figure 4. These products 
were the same assayed in vivo in a relative bioavailability 
study performed in healthy volunteers (28). Table 9 pres-
ents the results of the dissolution profile comparison. 
DISCUSSION
In this work, dissolution profiles were compared by 
different methods belonging to one of three main classes: 
model-dependent, ANOVA-based statistical methods, and 
model-independent methods. Within the first category, 
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Table 3. Summary of the Results Obtained with the Comparison Methods Applied to the Dissolution Profiles of Products J* and K 
of OxCBZ Tablets
Model-independent methods
K (T) vs J* (Ref) J* (T) vs K (Ref) Conclusion
f2 49.18 51.68 ND
f1 11.82 10.53 similar
ratio p 90% CI for the ratio
DE 0.9719 0.0601 95.55–98.86 similar
AUC 0.9772 0.2110 94.63–100.92 similar
ANOVA-based statistical methods
Two-factor p value One-factor p value
Formulation (F) <0.01 <0.01* not similar 
Time (T) <0.01
* Significant differences were found at 15. 30 and 45 minutes
not similar
FxT <0.01 not similar
Model-dependent methods
difference 90% CI for the difference
Weibull parameters
a -0.935 -1.553 to -0.317
not similar
b 0.466 0.284–0.649
calculated F critical F (95%) p
Hotelling’s T2 56.60 4.06 <0.001 not similar
DE: dissolution efficiency; AUC: area under the curve; CI: confidence interval; ND: not determined
Table 4. Summary of Results Obtained with the Comparison Methods Applied to Dissolution Profiles of Products J* and M of 
OxCBZ Tablets
Model-independent methods
M (T) vs J* (Ref) J* (T) vs M (Ref) Conclusion
f2 27.50 30.56 not similar
f1 32.38 30.95 not similar
ratio p 90% CI for the ratio
DE 0.9554 0.0161 93.64–97.47 not similar
AUC 0.9479 0.0744 92.03–97.63 similar
ANOVA-based statistical methods
Two-factor p value One-factor p value
Formulation <0.01 <0.01* not similar 
Time <0.01
* Significant differences  found at 5, 15, and 30 min
not similar
FxT <0.01 not similar
Model-dependent methods
difference 90% CI for the difference
Weibull parameters a -0.890 -1.613 to -0.167
not similar
b -0.113 -0.282 to 0.055
calculated F critical F (95%) p
Hotelling’s T2 35.07 4.06 <0.001 not similar
DE: dissolution efficiency; AUC: area under the curve; CI: confidence interval; ND: not determined
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Table 5. Summary of the Obtained Results with the Comparison Methods Applied to the Dissolution Profiles of Products K and M 
of OxCBZ Tablets
Model-independent methods
M (T) vs K (Ref) K (T) vs M (Ref) Conclusion
f2 39.82 39.82 not similar
f1 19.02 16.05 not similar
ratio p 90% CI for the ratio
DE 0.9830 0.0351 97.10–99.50 similar
AUC 0.9699 0.1879 93.12–101.03 similar
ANOVA-based statistical methods
Two-factor p value One-factor p value
Formulation <0.01 <0.01* not similar 
Time <0.01
* Significant differences were found at 5 and 15 minutes
not similar
FxT <0.01 not similar
Model-dependent methods
difference 90% CI for the difference
Weibull parameters a -1.825 -2.335 to -1.315
not similar
b 0.353 0.168–0.538
calculated F critical F (95%) p
Hotelling’s T2 82.10 4.06 <0.001 not similar
DE: dissolution efficiency; AUC: area under the curve; CI: confidence interval; ND: not determined.
Table 6. Summary of the Results Obtained with the Comparison Methods Applied to the Dissolution Profiles of OxCBZ Tablets L 
and M
Model-independent methods
M (T) vs L (Ref) L (T) vs M (Ref) Conclusion
f2 53.04 50.65 similar
f1 8.82 11.18 similar
ratio p 90% CI for ratio
DE 0.9778 0.0632 96.17–99.41 similar
AUC 0.9709 0.1058 94.21–100.07 similar
ANOVA-based statistical methods
Two-factor p value One-factor p value
Formulation <0.01 <0.01* not similar 
Time <0.01 * Significant differences were found at 15 
and 30 minutes
not similar
FxT <0.01 not similar
Model-dependent methods
difference 90% CI for the difference
Weibull parameters a 0.012 -0.706 to 0.729
similar
b -0.081 -0.238 to 0.077
calculated F critical F (95%) p
not similar
Hotelling’s T2 17.46 4.06 <0.001
DE: dissolution efficiency; AUC: area under the curve; CI: confidence interval; ND: not determined.
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comparisons were made in two ways: by the regions-
of-similarity method (5) and by Hottelling’s T2 test (26). 
Other methods have been proposed for these kinds of 
comparisons (11, 13, 14), but these two were chosen as 
representative of methods based on confidence regions 
and on hypothesis testing, respectively, while being easy 
to calculate and interpret.
Table 6 shows that the only OxCBZ products that were 
similar by a model-dependent method were OxCBZ-L 
and M, both products of the same brand in different 
doses (600 and 300 mg, respectively). The method was 
very discriminating; products L and M were similar only 
when the similarity region corresponding to ±3σ of the 
reference product (OxCBZ-J*) was considered. Moreover, 
since the reference product was the one with the highest 
parameter dispersion, the similarity would not have been 
established if that region was based on the dispersion of 
any other product. Methods based on confidence regions 
have additional disadvantages: the criterion to define the 
region of similarity is uncertain, it is difficult to interpret 
this region, and the production of more variable reference 
batches is encouraged to increase the chances of conclud-
ing similarity.
On the other hand, no pair of OxCBZ products could be 
considered similar according to the hypothesis test based 
on Hotelling’s T2 statistic. The mean parameters compared 
(a and b in this case) arise from fitting the model to each 
individual tablet. The dispersions normally found among 
Figure 3. Dissolution profiles in 1% LSNa of four brands of 200-mg CBZ tab-
lets products. The asterisk denotes the reference product.
Figure 4. Dissolution profiles in distilled water of two brands of 100-mg 
PHT capsules.
Table 7. Values of Parameters (k, a, b) Obtained by Fitting the Four Mathematical Models Described to the Dissolution Data of the 
CBZ 200-mg Products
Product First Order Gompertz Logistic Weibull
CBZ-A*
k = 0.0416 a = 13.98 a = -3.734 a = 0.0837
b = 2.587 b = 3.178 b = 0.7764
p < 0.01 p < 0.01 p < 0.01 p > 0.05
CBZ-B
k = 0.0291 a = 18.36 a = -4.365 a = 0.0451
b = 2.533 b = 3.293 b = 0.8740
p < 0.01 p < 0.01 p < 0.01 p < 0.01
CBZ-C
k = 0.0774 a = 87.22 a = -5.866 a = 0.0215
b = 4.739 b = 5.740 b = 1.4782
p < 0.01 p < 0.01 p > 0.05 p > 0.05
CBZ-D
k = 0.1221 a = 5.164 a = -1.999 a = 0.4122
b = 2.838 b = 3.048 b = 0.5284
p < 0.01 p < 0.01 p > 0.05 p > 0.05
p < 0.01 (bolded) indicates lack of fit.
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different tablets of a single batch yield a large variability 
in the estimates of these parameters, which results in a 
higher value of the T2 statistic, thereby increasing the 
requirement for establishing similarity. Another disadvan-
tage of hypothesis testing is that it only accepts or rejects 
the similarity between the data sets being compared, 
while dissolution analysis is more relevant to determine if 
the difference between two profiles is within acceptable 
limits, rather than determining whether or not they are 
different.
However, the possibility of evaluating the parameters 
separately that these methods allow is interesting, while 
considering the variances and covariances of the data. For 
example, for products K and M, both equation parameters 
were quite different; for the pair M-J*, parameter b was 
within the similarity region, while for J*-K, the same was 
true for parameter a. That is, the method is capable of 
detecting differences and similarities in shape (parameter 
b) and scale (parameter a) between dissolution profiles.
Meanwhile, ANOVA-based statistical methods proved 
unacceptable for use in the dissolution profile compari-
son analysis. In the two-way analysis, the large number 
of degrees of freedom because of the replicates (individ-
ual tablets) caused a large decrease in the residual term 
Table 8. Results of the Dissolution Profile Comparison of Four CBZ 200-mg Products Assayed
CBZ-Aa vs CBZ-B Conclusion
f2 52.40 (A)b 54.27 (B) similar
f1 11.86 (A) 10.72 (B) similar
Ratio (p) 90% CI for ratio  
DE 0.9419 (0.0031) 91.54–96.92 not similar
AUC 0.9478 (0.0043) 92.27–97.37 not similar
CBZ-Aa vs CBZ-C
f2 37.98 (A) 34.47 (C) not similar
f1 22.52 (A) 24.76 (C) not similar
DE 1.1081 (<0.001) 108.22–113.46 not similar
AUC 1.1074 (<0.001) 108.01–113.55 not similar
CBZ-Aa vs CBZ-D
f2 32.32 (A) 27.50 (D) not similar
f1 28.04 31.82 not similar
DE 1.1258 (<0.001) 106.04–119.52 not similar
AUC 1.1162 (<0.001) 106.28–117.23 not similar
CBZ-B vs CBZ-C
f2 31.09 (B) 25.59 (C) not similar
f1 30.86 38.31 not similar
DE 1.1765 (<0.001) 115.76–119.57 not similar
AUC 1.1684 (<0.001) 114.14–119.60 not similar
CBZ-B vs CBZ-D
f2 27.26 (B) 20.76 (D) not similar
f1 35.59 44.10 not similar
DE 1.1744 (<0.001) 115.02–119.92 not similar
AUC 1.1656 (<0.001) 113.80–119.38 not similar
CBZ-C vs CBZ-D
f2 40.58 (C) 40.58 (D) not similar
f1 14.44 13.08 similar
DE 1.0064 (0.4824) 98.83–102.49 similar
AUC 1.0045 (0.8525) 98.63–102.30 similar
a Actual reference product.
b Letter in parentheses indicates product taken as the reference.
DE: dissolution efficiency; AUC: area under the curve; CI: confidence interval.
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and in the critical value (F), resulting in a higher demand 
for the establishment of similarity. Therefore, this test 
identifies statistical instead of pharmaceutical differenc-
es among dissolution profiles. When only the factor “for-
mulation” was considered and comparisons were made 
time to time, the method was inefficient because the 
type I error was greater than the nominal value of 5%, 
besides being tedious and the interpretation ambiguous. 
In this work, no pair of products was similar according to 
these methods.
Hence, the model-independent method was the most 
suitable for assessing equivalence in dissolution behavior 
between multisource products. However, OxCBZ data 
presented in Tables 3–6 show that the results of the AUC 
and DE comparison were not always coincident with the f 
indexes.
Analysis of CBZ results shows that the profiles of CBZ-A* 
and CBZ-B products (the two curves below the others in 
Figure 3) were similar according to the f1 and f2 factors, 
but not with respect to AUC and DE (p < 0.005). The pair of 
products CBZ-C and CBZ-D represent the opposite situa-
tion; they were similar according to AUC and DE but not to 
the f2 criterion.
These situations clearly illustrate the nature of both 
types of comparisons. The f2 factor accounts for the differ-
ences in the percentage dissolved by measuring vertical 
distances regardless of its position in the time axis (i.e., 
does not consider the spacing between points). This 
makes f2 very sensitive to the differences in the first time 
points, which may not affect the area or the final shape of 
the profile. Figure 3 shows that the CBZ-C dissolution pro-
file is not too different from the CBZ-D profile, except in 
the first two time points sampled where it remains below. 
This had a major impact on f2, which was calculated with 
only the first three time points, since the products were 
rapidly dissolving (i.e., up to 85% before 30 min). However, 
the AUC (and the DE) did not differ significantly between 
the two products.
The aforementioned is the foundation of our proposal: a 
combined approach between the f2 index (a rate or shape 
indicator) and the result of the AUC or DE comparison (as 
amount parameters). This approach yields a more biorel-
evant measure able to detect if the two given profiles are 
similar in speed and amount dissolved, or in only one of 
them.
The results obtained in vivo when these four CBZ prod-
ucts were assayed in healthy volunteers (27) showed that:
• Product B was equivalent to A* in terms of rate (the 
Cmax/ABC0-t and Tmax parameters were bioequivalent) 
but not in amount absorbed (AUC0-t, AUC0-∞, and Cmax 
were not bioequivalent).
• Products C and D were equivalent in amount absorbed 
(AUC0-t and Cmax were bioequivalent) and almost in ab-
sorption rate (the 90% confidence interval for the Cmax/
AUC0-t  parameter was 78.2–122.9%).
These results support our previous analysis that 
whereas the f2 factor is related to the in vivo absorption 
rate, the AUC and DE parameters are related to the in vivo 
absorbed amount.
The results obtained for PHT illustrate another aspect 
of these comparison methods. The two products tested 
(PHT-F and G) were bioequivalent in vivo even according 
to the individual bioequivalence methodology applied 
(28), but their dissolution profiles were only equivalent in 
terms of their AUC and DE (p > 0.05 ), with f2 < 50 (Table 9).
We do not believe that these results disagree with the 
previous ones, but instead further support the proposal 
of the combined report of the f2 index with the AUC or DE 
comparison result. However, bioequivalence between F 
and G means similar rates and amounts absorbed in vivo 
and could probably be established due to the high in vitro 
dissolution rate found for both products. Although PHT 
belongs to BCS Class 2 (29), the tested capsules demon-
strated rapid dissolution in water (>85% in 30 min). That 
is, the differences detected by f2 were not biorelevant 
due to the rapid dissolution of the products in water, the 
comparison of AUC and DE being more suitable.
Finally, by simultaneously reporting two comparison 
results, more evidence is available to determine the simi-
larity of dissolution profiles, particularly in those situations 
where f2 is near the specification (50) or when it is greater 
or less than 50 depending on which product is taken as 
the reference for the calculation. For example, OxCBZ-
J* and K products (Table 3) have an f2 of 51.68 or 49.18 
depending on which of them is used as the reference. The 
result of the AUC and DE comparison could then become 
the biopharmaceutical support of the dissolution profile 
similarity decision. 
CONCLUSION
There are many reasons for the comparison of dissolu-
tion profiles: to evaluate the dissolution performance of a 
new product during the preformulation stage as a part of 
stability studies, to assess the impact of scale-up and post-
approval changes, or to compare the biopharmaceutical 
in vitro performance of multisource products to ensure 
similar in vivo product performance (16). Biowaivers (2) are 
Table 9. Results of the Dissolution Profile Comparison of the 
PHT 100-mg Products 
PHT-F vs PHT-G Conclusion
f2 39.05 (F)a 35.94 (G) not similar
f1 17.06 (F) 20.79 (G) similar
Ratio (p) 90% CI for ratio
DE 1.0178 (0.0671) 100.30–103.27 similar
AUC 1.0228 (0.2224) 99.11–105.36 similar
a Letter in parentheses indicates product taken as the reference.
DE: dissolution efficiency; AUC: area under the curve; CI: confidence interval.
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an example of the latter (i.e., products for which the classic 
in vivo bioequivalence studies are replaced by in vitro dis-
solution studies).
Our results show that for such situations, model-indepen-
dent methods are the most suitable for profile comparison. 
ANOVA-based statistical methods do not meet the funda-
mental hypothesis of independence between observations 
when applied to percentage dissolved, and therefore the 
data processing is not appropriate. On the other hand, 
model-dependent methods are over discriminating and not 
easy to calculate, as they require model selection, fitting 
of the model to dissolution data of each individual tablet 
(these two steps present few difficulties with the right soft-
ware, but are time-consuming), and then calculation of the 
statistical comparison, which requires training in the spe-
cific statistical software. However, the major disadvantage 
of these methods is that by requiring that the data fit some 
descriptive equation, they fail when applied to the compari-
son of multisource products that hardly fit the same model, 
as occurred with CBZ results. The same authors who de-
veloped the similarity-region method (5) stated that it was 
primarily intended for application in the analysis of changes 
in product dissolution behavior produced by scaling or 
changes subsequent to the product approval (scale-up and 
post-approval changes). 
When the biopharmaceutical quality of multisource drug 
products is compared through in vitro dissolution studies, 
the current recommended method (similarity factor, f2) is 
suitable, although in certain situations may be insufficient 
or have ambiguous interpretation. A recent study by Duan 
et al. (30) analyzed the correspondence between the f2 and 
in vivo results obtained by simulations, and concluded that 
although the results were consistent in most cases, care 
should be taken when the completeness of the dissolution 
profiles differ more than 10% or when the shapes of the 
dissolution profiles are significantly different.
To address these and other inherent limitations of the 
f2 factor, we proposed a combined approach: to report 
f2 along with the result of the AUC or DE comparison as 
quantity indicators. Thereby a more robust and reliable 
result that provides more information for the interpreta-
tion of the comparison is obtained. The proposed method 
is simple, fast, and easy to calculate and interpret, requir-
ing no sophisticated software.
Finally, this approach provides extra arguments when 
deciding if two profiles are similar, as it allows a bet-
ter description of the dissolution process (i.e., rate and 
amount dissolved) and thus a better prediction of in vivo 
performance, which is the ultimate goal when comparing 
multisource, and potentially therapeutically equivalent, 
products.
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